The Insertion/Deletion Polymorphism in the t-PA Gene Does Not Significantly Affect Outcome of Meningococcal Disease

• References

• 1 Hart DA, Rehemtulla A. Plasminogen activators and their inhibitors: regulators of extracellular proteolysis and cell function. Comp Biochem Physiol B 1988; 90: 691-708.
• 2 Brandtzaeg P, Joo GB, Brusletto B, Kierulf P. Plasminogen activator 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 1990; 57: 271-8.
• 3 Kornelisse RF, Hazelzet JA, Savelkoul HFJ, Hop WCJ, Suur MH, Borsboom ANJ, Risseeuw-Appel IM, van der Voort E, de Groot R. The relationship between plasminogen activator inhibitor-1, proinflammatory and counterinflammatory mediators in children with meningococcal septic shock. J Infect Dis 1996; 173: 1148-56.
• 4 Zenz W, Muntean W, Gallistl S, Zobel G, Grubbauer HM. Recombinant tissue plasminogen activator treatment in two infants with fulminant meningococcaemia. Paediatrics 1995; 96: 144-7.
• 5 Keeley SR, Matthews NT, Buist M. Tissue plasminogen activator for gangrene in fulminant meningococcaemia. Lancet 1991; 337: 1359
• 6 Ludwig M, Wohn KD, Schleuning WD, Olek K. Allelic dimorphism in the human tissue-type plasminogen activator (TPA) gene as a result of an Alu insertion/deletion event. Hum Genet 1992; 88: 388-92.
• 7 Miura O, Sugahara Y, Nakamura Y, Hirosawa S, Aoki N. Restriction fragment length polymorphism caused by a deletion involving Alu sequences within the human alpha 2-plasmin inhibitor gene. Biochemistry 1989; 28: 4934-8.
• 8 Pollack MM, Ruttimann UE, Getson PR. Pediatric risk of mortality (PRISM) score. Crit Care Med 1988; 16: 1110-6.
• 9 Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De-Vos R, van-den-Oord JJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-24.